Cervical spondylotic myelopathy can be surgically treated by either ventral or dorsal decompression and fusion. However, there is a lack of high-level evidence on the relative advantages and disadvantages for these treatments of CSM. The authors’ goal was to provide a comprehensive review of the relative benefits of ventral versus dorsal fusion in terms of quality of life (QOL) outcomes, complications, and costs. They reviewed 7 studies on CSM published between 2003 and 2013 and summarized the findings for each category. Both procedures have been shown to lead to statistically significant improvement in clinical outcomes for patients. Ventral fusion surgery has been shown to yield better QOL outcomes than dorsal fusion surgery. Complication rates for ventral fusion surgery range from 11% to 13.6%, whereas those for dorsal fusion surgery range from 16.4% to 19%. Larger randomized controlled trials are needed, with particular emphasis on QOL and minimum clinically important differences. (http://thejns.org/doi/abs/10.3171/2013.4.FOCUS13103)

Key Words • ventral fusion • dorsal fusion • cervical fusion • cervical spondylotic myelopathy • anterior cervical discectomy and fusion

Abbreviations used in this paper: CSM = cervical spondylotic myelopathy; EQ-5D = EuroQol–5 Dimensions health survey; MCID = minimum clinically important difference; mJOA = modified Japanese Orthopaedic Association; NDI = Neck Disability Index; NIS = Nationwide Inpatient Sample; QALY = quality-adjusted life year; QOL = quality of life; SF-36, SF-6D = 36-Item Short Form Health Survey, Short Form–6 Dimensions.
Methods

A MEDLINE review of English-language literature was performed to identify studies comparing ventral multilevel discectomy and fusion with dorsal cervical fusion performed between 2003 and 2013. This time period was chosen to focus on only the most recent studies relevant to current clinical practice. The search terms included ventral cervical fusion, anterior cervical fusion, dorsal cervical fusion, posterior cervical fusion, cervical spondylotic myelopathy, and CSM. A total of 3512 results were retrieved from these searches. Furthermore, references from the identified studies as well as those from other review papers were used to ensure completeness. Studies were excluded if they did not pertain to ventral and dorsal fusion surgery for CSM. A total of 235,549 patients undergoing ventral (n = 46,766) or dorsal (n = 82,411) fusion surgery for CSM were analyzed. Also in 2012, Whitmore et al.22 conducted a retrospective study on patients with CSM who were included in the AOSpine North America Cervical Spondylotic Myelopathy Study (n = 70 cases; 45 patients in the ventral fusion cohort and 19 in the dorsal fusion cohort; 6 patients had both). The QOL outcomes measured by the mJOA (3-point increase), NDI (11-point decrease), SF-36 (5-point increase), and SF-6D (0.07-point increase) all showed significant (p < 0.0001) improvement by 1 year postoperatively. Thus, in agreement with Ghogawala et al., they found that surgical management of CSM produces significantly improved QOL outcomes. However, this study did not make specific comparisons between ventral and dorsal fusion cohorts.

Results

Seven studies (1 prospective, 6 retrospective) consisting of 248,029 patients were identified and reviewed. Table 1 provides a summary of QOL outcomes assessed for the 2 procedures, Table 2 summarizes complications for each approach, and Table 3 summarizes the financial costs and cost-effectiveness studies associated with each approach.

Studies of QOL Outcomes

Three studies (1 prospective, 2 retrospective) consisting of 192 patients undergoing ventral (n = 114), dorsal (n = 72), or ventral and dorsal (n = 6) fusion surgery for CSM were analyzed (Table 1). Outcome measures included the SF-36, SF-6D, EQ-5D, mJOA, and NDI. All 3 studies had a 1-year follow-up and reported significantly (p < 0.05) improved QOL outcomes for some or all of these questionnaires from the preoperative to postoperative period.

Of these studies, the highest level of evidence was in the investigation by Ghogawala et al., who conducted a prospective study on patients (n = 50) with CSM undergoing either ventral (n = 28) or dorsal (n = 22) fusion. Both cohorts showed significant preoperative to postoperative improvement in mJOA (ventral: 2-point increase, p < 0.01; dorsal: 1.9-point increase, p < 0.01); EQ-5D (ventral: 0.16-point increase, p < 0.01; dorsal: 0.13-point increase, p = 0.04); and SF-36 scores (ventral: 9.9-point increase, p < 0.01; dorsal: 5.7-point increase, p = 0.03). In addition, the ventral cohort showed significant preoperative to postoperative improvement in the NDI score (18.4-point decrease, p < 0.01), and had significantly greater improvements only in the SF-36 score compared with the dorsal cohort. Although greater improvement for the SF-36 score was observed after ventral fusion, the dorsal cohort had a greater degree of myelopathy preoperatively than the ventral cohort, which may have confounded the results.

In 2012, Fehlings et al.3 conducted a retrospective study of patients with CSM who were included in the AOSpine North America Cervical Spondylotic Myelopathy Study (n = 70 cases; 45 patients in the ventral fusion cohort and 19 in the dorsal fusion cohort; 6 patients had both). The QOL outcomes measured by the mJOA (3-point increase), NDI (11-point decrease), SF-36 (5-point increase), and SF-6D (0.07-point increase) all showed significant (p < 0.0001) improvement by 1 year postoperatively. In addition, the dorsal cohort on average had more levels surgically treated (3.1 vs 2.1 for ventral, p < 0.01) and was associated with a longer hospital stay (4 days vs 2.6 days) compared with the ventral cohort. Overall, both ventral and dorsal fusion surgery for CSM showed significant improvement in disease-specific symptoms and in QOL measures. The investigators concluded that a randomized controlled trial was needed to determine more accurately the optimal fusion approach for patients with CSM.

Studies of Complications

Four studies (1 prospective, 3 retrospective) consisting of 235,549 patients undergoing ventral (n = 46,766) or dorsal (n = 82,411) fusion surgery for CSM were analyzed...
Ventral versus dorsal fusion for cervical spondylotic myelopathy

The overall complication rate ranged from 6.5% to 16.6%. Complication rates for ventral fusion surgery ranged from 11% to 13.6%, whereas those for dorsal fusion surgery ranged from 16.4% to 19%. Complications included hoarseness, cardiopulmonary dysfunction, dysphagia, wound infection, sensory loss, weakness, and death. Patients who underwent multilevel ventral decompression and fusion had a higher rate of hoarseness and dysphagia, whereas those who underwent dorsal fusions had a higher rate of neck pain or nerve palsies.

In 2007, Wang et al. used the NIS to retrospectively review the medical records of 932,009 patients who underwent cervical spine surgery for degenerative disease (19% with CSM) between 1992 and 2001. Patients with CSM who underwent surgery had the highest complication rate (6.5%) and in-hospital mortality rate (0.39%) compared with the rates for other types of cervical spine surgery.

Boakye et al. also used the NIS database to review 58,115 patients with CSM undergoing surgery between 1993 and 2002. These investigators reported an overall complication rate of 13.4% (16.4% for dorsal fusion, 11.9% for ventral fusion; no p value reported). Pulmonary (3.6%) and postoperative hemorrhages or hematomas (2.3%) were the most common complications for both ventral and dorsal fusion. Dysphagia (3%) and hoarseness (0.21%) were more prevalent in the ventral cohort. Pulmonary complications (4.6%) and hematomas (3.2%) were more prevalent in the dorsal cohort. Other complications for both cohorts included renal (1.45%), cardiac (1.2%), thromboembolic (0.73%), neurological (0.71%), and infection (0.43%).

Boakye et al. showed that complication profiles did not significantly differ between ventral and dorsal cohorts (13.6% vs 17.9% for ventral and dorsal approach cohorts, respectively; p = 1.0). The overall complication rate was 16.6%. The dorsal cohort had greater rates of postoperative pain and disability compared with the vent-

### TABLE 1: Studies of outcomes for ventral and dorsal fusion*

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Study Design</th>
<th>Evidence Class†</th>
<th>Mean FU</th>
<th>Patient Sample</th>
<th>Outcome Measure</th>
<th>1-Yr Improvement, Ventral vs Dorsal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghogawala et al., 2011</td>
<td>prospective cohort</td>
<td>II</td>
<td>1 yr</td>
<td>50 overall</td>
<td>SF-36</td>
<td>9.9 vs 5.7 (p = 0.03)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28 ventral</td>
<td>NDI</td>
<td>18.4 vs 5.9 (p = 0.07)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22 dorsal</td>
<td>EQ-5D</td>
<td>0.16 vs 0.13 (p = 0.13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mJOA</td>
<td>2.0 vs 1.9 (p = 0.16)</td>
</tr>
<tr>
<td>Whitmore et al., 2012</td>
<td>retrospective cohort</td>
<td>III</td>
<td>1 yr</td>
<td>72 overall</td>
<td>SF-36</td>
<td>8.5 vs 4.7 (p = 0.12)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>41 ventral</td>
<td>NDI</td>
<td>16.3 vs 10.8 (p = 0.22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31 dorsal</td>
<td>EQ-5D</td>
<td>0.16 vs 0.13 (p = 0.56)</td>
</tr>
<tr>
<td>Fehlings et al., 2012</td>
<td>retrospective case series</td>
<td>III</td>
<td>1 yr</td>
<td>70 overall‡</td>
<td>SF-36</td>
<td>ventral/dorsal comparisons not made</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>45 ventral</td>
<td>NDI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19 dorsal</td>
<td>mJOA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SF-6D</td>
<td></td>
</tr>
</tbody>
</table>

* FU = follow-up.
† Level of evidence according to Resnick et al.
‡ Six patients had both ventral and dorsal fusion.

### TABLE 2: Studies of complications for ventral and dorsal fusion*

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Study Design</th>
<th>Evidence Class</th>
<th>Mean FU</th>
<th>Patient Sample</th>
<th>Complication(s)</th>
<th>Complication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang et al., 2007</td>
<td>retrospective case series</td>
<td>III</td>
<td>10 yrs</td>
<td>932,009 overall (~177,082 CSM patients)</td>
<td>hoarseness, infection, systemic</td>
<td>6.5% overall</td>
</tr>
<tr>
<td>Boakye et al., 2008</td>
<td>retrospective case series</td>
<td>III</td>
<td>10 yrs</td>
<td>58,115 overall</td>
<td>pulmonary hemorrhages, hematomas</td>
<td>13.4% overall</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>46,562 ventral</td>
<td>11.9% ventral</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8,112 dorsal</td>
<td>16.4% dorsal</td>
<td></td>
</tr>
<tr>
<td>Ghogawala et al., 2011</td>
<td>prospective cohort</td>
<td>II</td>
<td>1 yr</td>
<td>50 overall</td>
<td>dysphagia, C-5 palsies</td>
<td>16.6% overall</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28 ventral</td>
<td>13.6% ventral</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22 dorsal</td>
<td>17.9% dorsal</td>
<td></td>
</tr>
<tr>
<td>Fehlings et al., 2012</td>
<td>retrospective case series</td>
<td>III</td>
<td>2 yrs</td>
<td>302 overall</td>
<td>dysphagia, infection, minor CPEs, neck pain</td>
<td>15.6% overall</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>176 ventral</td>
<td>11% ventral</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>107 dorsal</td>
<td>19% dorsal</td>
<td></td>
</tr>
</tbody>
</table>

* CPE = cardiopulmonary event.
Of those patients in the ventral cohort who had complications, 80% had swallowing difficulties. The 3 patients (13.6%) in the dorsal cohort with complications each had C-5 palsy. Although the investigators did not define what was considered to be C-5 palsy (for example, loss of motor strength, sensory loss, pain in the C-5 distribution), this percentage is high compared with what has been reported in the literature.14

Fehlings et al.4 analyzed 302 patients from the AOSpine North America Cervical Spondylotic Myelopathy Study who underwent surgical treatment for CSM. These investigators reported an overall perioperative complication (for example, infection, bleeding, dural tear, esophageal injury) rate of 15.6%, with an overall delayed complication (for example, pseudarthrosis, hardware breakage, graft dislodgement) rate of 4.4%. The ventral and dorsal cohorts had complication rates of 11% and 19%, respectively (p = 0.11). The most common complications included cardiopulmonary (3%), dysphagia (3%), and wound infection (2.3%). Operative blood loss was significantly (p < 0.01) greater in the dorsal cohort compared with the ventral cohort. The dorsal cohort also had a significantly (p = 0.03) greater incidence of wound infection (4.7%) compared with the ventral cohort (0.6%).

Studies of Cost-Effectiveness

Five studies (1 prospective, 4 retrospective) consisting of 70,645 patients undergoing ventral (n = 57,125) or dorsal (n = 8365) fusion surgery for CSM were analyzed (Table 3). Of these 5 studies, the 4 that included cohorts of ventral versus dorsal fusion surgery all showed that costs were greater for dorsal when compared with ventral fusion surgery.

Fehlings et al.3 calculated the financial costs and cost-effectiveness of both ventral and dorsal fusion surgery for patients with CSM. Direct costs on average for both fusion surgeries were $21,066 Canadian ($20,516 US). The cost-utility ratio was $32,916 Canadian/QALY gained, allowing the investigators to conclude that surgical management of CSM is cost-effective based on thresholds for cost-effectiveness in the literature.

Boakye et al.1 analyzed data from the NIS database to estimate an average total cost of both ventral and dorsal fusion surgery for CSM to be $25,419. Dorsal fusion surgery had significantly greater costs ($30,927) than ventral fusion surgery ($23,209). King et al.9 performed a retrospective review of the Washington State Inpatient Database (1998–2002) that used a published algorithm for identifying cervical spine surgery admissions related to cervical spine degenerative disease (not CSM specific). Hospital charges were significantly (p < 0.01) greater for dorsal ($23,400) compared with ventral ($14,300) fusion surgery (2.3-year mean follow-up).

Similarly, Ghogawala et al.5 showed that dorsal fusion surgery was associated with significantly greater costs ($29,465) than ventral fusion surgery ($19,245) in a 1-year follow-up. Costs were derived by combining Medicare reimbursements or cost-to-charge ratios with actual hospital charges.

Whitmore et al.22 also conducted a cost analysis by using 2 different cost calculation methodologies: cost-to-charge ratios and Medicare reimbursement. Using the former, the investigators found that dorsal fusion surgery had significantly greater costs ($29,465) than ventral fusion surgery ($19,245) in a 1-year follow-up. Costs were derived by combining Medicare reimbursements or cost-to-charge ratios with actual hospital charges.

Whitmore et al.22 also conducted a cost analysis by using 2 different cost calculation methodologies: cost-to-charge ratios and Medicare reimbursement. Using the former, the investigators found that dorsal fusion surgery had significantly greater costs ($29,465) than ventral fusion surgery ($19,245) in a 1-year follow-up. Costs were derived by combining Medicare reimbursements or cost-to-charge ratios with actual hospital charges.

Whitmore et al.22 also conducted a cost analysis by using 2 different cost calculation methodologies: cost-to-charge ratios and Medicare reimbursement. Using the former, the investigators found that dorsal fusion surgery had significantly greater costs ($29,465) than ventral fusion surgery ($19,245) in a 1-year follow-up. Costs were derived by combining Medicare reimbursements or cost-to-charge ratios with actual hospital charges.

Whitmore et al.22 also conducted a cost analysis by using 2 different cost calculation methodologies: cost-to-charge ratios and Medicare reimbursement. Using the former, the investigators found that dorsal fusion surgery had significantly greater costs ($29,465) than ventral fusion surgery ($19,245) in a 1-year follow-up. Costs were derived by combining Medicare reimbursements or cost-to-charge ratios with actual hospital charges.


table 3: studies of costs and cost-effectiveness for ventral and dorsal fusion*

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Study Design</th>
<th>Evidence Class</th>
<th>Mean FU</th>
<th>Patient Sample</th>
<th>QALYs</th>
<th>Mean Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fehlings et al., 2012</td>
<td>retrospective case series</td>
<td>III</td>
<td>1 yr</td>
<td>70 overall</td>
<td>0.07/yr, 0.64/10 yrs</td>
<td>$21,066 overall†</td>
</tr>
<tr>
<td>Boakye et al., 2008</td>
<td>retrospective case series</td>
<td>III</td>
<td>10 yrs</td>
<td>58,115 overall</td>
<td>NA</td>
<td>$23,209 ventral</td>
</tr>
<tr>
<td>King et al., 2009</td>
<td>retrospective cohort</td>
<td>III</td>
<td>2.3 yrs</td>
<td>12,338 overall</td>
<td>NA</td>
<td>$14,300 ventral</td>
</tr>
<tr>
<td>Ghogawala et al., 2011</td>
<td>prospective cohort</td>
<td>II</td>
<td>1 yr</td>
<td>50 overall</td>
<td>NA</td>
<td>$19,245 ventral</td>
</tr>
<tr>
<td>Fehlings et al., 2012</td>
<td>retrospective case series</td>
<td>III</td>
<td>1 yr</td>
<td>70 overall</td>
<td>0.16/yr ventral</td>
<td>$21,563 ventral (CCR)</td>
</tr>
<tr>
<td>Whitmore et al., 2012</td>
<td>retrospective cohort</td>
<td>III</td>
<td>1 yr</td>
<td>72 overall</td>
<td>0.13/yr dorsal</td>
<td>$24,065 dorsal</td>
</tr>
</tbody>
</table>

* CCR = cost-to-charge ratio method; MED = Medicare reimbursement method; NA = not applicable.
† This amount is given in Canadian dollars ($20,516 US); the rest of the costs are given in US dollars.
Ventral versus dorsal fusion for cervical spondylotic myelopathy

were not significantly different (dorsal: $16,579, ventral: $17,538), and the incremental cost-effectiveness ratio for ventral fusion was $34,533/QALY gained. This study highlighted how different conclusions can be reached relative to cost-effectiveness or significant differences in cost depending on which cost methodology is used. Notably, there is much heterogeneity in the literature regarding methods by which both “costs” and “cost-effectiveness” have been measured to date.

Discussion

Patients with CSM commonly present with varying patterns of trunk or extremity numbness, neck pain, loss of hand dexterity, motor weakness in the upper extremities, and gait disturbances. Although the first-line treatment in the majority of patients is conservative management (including cervical immobilization via a neck collar or brace and physical therapy), surgical decompression and/or fusion is often indicated in patients with progressive neurological demise with correlative spinal cord compression. There are various surgical techniques that are commonly used. The choice of surgical procedure will vary based on the individual patients, the region of pathology, number of levels involved, cervical alignment, presence or absence of neck pain, and surgeon preference. In all patients, however, the goal of the surgery is to decompress the spinal cord, preserve alignment and stability of the spinal column, and prevent further injury.

Regardless of the approach, early operative intervention can lead to superior outcomes. Suri et al. showed in a prospective study of 146 patients that those with less than a 1-year duration of symptoms had significantly superior outcomes postoperatively (that is, motor/sensory/autonomic/disability improvement) compared with those who had a longer duration of symptoms.

The present review demonstrated that both ventral and dorsal fusion result in significantly improved postoperative QOL compared with preoperatively. The 2 studies compared QOL outcomes for ventral versus dorsal fusion surgery demonstrated that ventral fusion leads to superior results, although in only one of these studies were these findings statistically significant. Limitations of the studies included retrospective study design, small patient samples, and short follow-up time (1 year). More prospective, well-designed studies are needed for better clarification of the QOL outcomes of these surgeries.

In addition, the included studies suggest that the complication rates and costs are significantly greater for dorsal fusion compared with ventral fusion. However, the complication rates for ventral fusion are also high and must be considered when consulting patients. To explain the cost differences between the 2 procedures, Whitmore et al. showed that there were significantly higher in-hospital charges for dorsal fusion. The Boakye et al., King et al., and Ghogawala et al. studies do not provide detailed descriptions of their cost data or explanations for this difference, and this makes it difficult to accurately assess and make comparisons between the groups in these studies regarding “costs.” The costs of some of the studies reviewed here did not include all relevant direct costs, including outpatient imaging technician fees or physical therapy and rehabilitation fees, or indirect costs to patients, such as loss of productivity and caregiver costs. Future cost-effectiveness analyses should include detailed descriptions of the cost differences for a better explanation of the true cost-effectiveness differences between ventral and dorsal fusion for CSM.

Many of the studies reviewed here focused exclusively on statistically significant differences and did not ascertain clinical relevance. Clinically significant meaning has become increasingly important in assessing treatment options. The MCID for anterior cervical discectomy and fusion (ventral fusion) has recently been investigated by Parker et al. The MCID represents the critical threshold necessary to achieve treatment effectiveness and be beneficial to the patient. Many studies have evaluated the MCID for the questionnaires used in the studies discussed herein, including the visual analog scale, NDI, and EQ-5D. The reported MCID will be different depending on the type of procedure (for example, ventral and dorsal fusion). By identifying the clinically meaningful improvements for each of these surgeries (that is, based on patient reports of QOL), investigators will be better able to ascertain cost-effectiveness and to comparative the effectiveness of the 2 procedures.

We acknowledge certain limitations that must be considered when interpreting the results of the present review. First, as in any systematic review, we include data from multiple studies and multiple surgeons with differing techniques and data collection and reporting methods. These differences, including differences in the reporting of major and minor complications, may somewhat confound the overall results. Second, nearly all of these studies represent Class III evidence, which is mainly retrospective. Studies of this design type may not account for differences in the patient sample with regard to comorbidities or the number of levels that were surgically treated. Wang et al. and Boakye et al. in particular used the NIS, which is the largest publicly available inpatient care database in the US, updated annually, with approximately 8 million hospital stays. Databases of this nature may be associated with significant sampling bias and coding errors that can confound results. The clinical data reviewed represent the low quality of evidence currently available and indicate the need for more well-designed prospective studies of this commonly encountered disease process.

In 2009, Mummaneni et al. performed a systematic review to compare the efficacy of different surgical techniques, including ventral and dorsal fusion, for the treatment of CSM. The investigators found insufficient evidence to recommend ventral fusion over dorsal fusion because both produced comparable improvement in patients with CSM. Notably, this conclusion was based on Class III evidence, most of which was published more than 10 years ago, none of which incorporated cost or QOL data. Their study further supports the need for studies with better levels of evidence that include cost and QOL outcomes.

Finally, studies focusing solely on ventral corpectomy and fusion or laminoplasty were not included. Compared with multilevel discectomy and fusion, ventral corpec-
tomy has been shown to have higher complication rates, including graft dislodgements and fusion failure.\textsuperscript{7,18,20} However, ventral corpectomy has been shown to yield similar QOL outcomes to ventral multilevel discectomy and fusion and, thus, should be investigated further in the future.\textsuperscript{12} In addition to ventral and dorsal fusion, laminoplasty is also commonly used in the surgical treatment of patients with CSM. This approach leads to comparable postoperative improvement in CSM symptoms and has a complication rate of approximately 12%, which is within the same range as ventral and slightly below that of dorsal fusion.\textsuperscript{4,12} Despite these limitations, the present review summarizes the current state of the literature published over the past decade and offers guidance to future research on the topic.

Conclusions

We have summarized the studies from the past decade and have found that both ventral and dorsal fusion surgeries lead to significantly improved QOL outcomes in patients with CSM. Controversy remains regarding the preferred surgery for this patient population. Recent studies have shown that dorsal fusion has both a higher complication rate and costs significantly more than ventral fusion. Most of the studies we reviewed, however, were Class III evidence, and therefore prospective studies are needed for a better comparison of the outcomes of the 2 surgical procedures. Furthermore, a greater focus on MCID values and clinically relevant findings is needed, to supplement the traditional use of statistical significance. Finally, cost-effectiveness analyses need to be more comprehensive (including more of the indirect costs) to understand better the true costs, cost-effectiveness, and comparative effectiveness of ventral versus dorsal fusion for CSM.

Disclosure

Dr. Mroz owns stock in PearlDiver, Inc., he is a consultant for Globus, and he receives fellowship support and speaking honors from AOSpine. No grant, technical, or corporate support was received in conducting this study or writing this manuscript.

Author contributions to the study and manuscript preparation include the following. Conception and design: Mroz. Acquisition of data: Alvin. Analysis and interpretation of data: Alvin. Drafting the article: Alvin. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Mroz. Study supervision: Mroz, Benzel.

References

Ventral versus dorsal fusion for cervical spondylotic myelopathy


Manuscript submitted March 14, 2013. Accepted April 10, 2013. Please include this information when citing this paper: DOI: 10.3171/2013.4.FOCUS13103.
Address correspondence to: Thomas E. Mroz, M.D., Neurological Institute, Cleveland Clinic Center for Spine Health, Departments of Orthopaedic and Neurological Surgery, The Cleveland Clinic, 9500 Euclid Ave., S-80, Cleveland, OH 44195. email: mroz@ccf.org.